Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03456076 · FLOW

Participant flow

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer · Source last updated 2026-07-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received 600 mg oral alectinib twice daily (BID) for 2 years
    id
    FG000
    title
    Alectinib
  2. description
    Participants received platinum-based chemotherapy for 4 cycles (cycle length = 21 days).
    id
    FG001
    title
    Platinum-Based Chemotherapy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        9
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Protocol deviation
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        111
      type
      Study ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        130
      2. group Id
        FG001
        num Subjects
        127
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        130
      2. group Id
        FG001
        num Subjects
        127
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Participants received 600 mg oral alectinib twice daily (BID) for 2 years
    id
    FG000
    title
    Alectinib
  2. description
    Participants received platinum-based chemotherapy for 4 cycles (cycle length = 21 days).
    id
    FG001
    title
    Platinum-Based Chemotherapy
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        5
      2. group Id
        FG001
        num Subjects
        9
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Protocol deviation
    3. reasons
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        1
      type
      Lost to Follow-up
    4. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        5
      type
      Death
    5. reasons
      1. group Id
        FG000
        num Subjects
        123
      2. group Id
        FG001
        num Subjects
        111
      type
      Study ongoing
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        130
      2. group Id
        FG001
        num Subjects
        127
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        0
      2. group Id
        FG001
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        130
      2. group Id
        FG001
        num Subjects
        127
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice